STAT+: Lilly’s breast cancer combo wins approval

Radiopharma players merge after a surprise FDA rejection, Novo plans to expand its pipeline, and more biotech news Scott Olson/Getty Images Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! Today we have some consolidation in radiopharma, an early ADHD signal for orexin agonists, and a call from Reed Jobs to double NIH funding. I like that Jobs wants biology to be treated as a space race. I also want more racing to space. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe